Working… Menu

Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029) (PURSUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01144416
Recruitment Status : Completed
First Posted : June 15, 2010
Results First Posted : December 27, 2012
Last Update Posted : June 30, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to show that a single injection of SCH 900962/MK-8962 is non-inferior to daily injections of recombinant follicle-stimulating hormone (recFSH) during the first week of ovarian stimulation in terms of the number of vital pregnancies (ie, presence of at least one fetus with heart activity as assessed by ultrasound at least 35 days after embryo transfer) in women aged 35 to 42 years undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Condition or disease Intervention/treatment Phase
Infertility Biological: SCH 900962 / Corifollitropin alfa / Org 36286 Biological: RecFSH / follitropin beta Drug: Placebo for SCH 900962 Drug: Placebo for recFSH Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1424 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)
Study Start Date : June 2010
Actual Primary Completion Date : July 2011
Actual Study Completion Date : April 2012

Arm Intervention/treatment
Experimental: Single injection of 150 µg SCH 900962 (MK-8962)
Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
Biological: SCH 900962 / Corifollitropin alfa / Org 36286
SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
Other Name: MK-8962

Drug: Placebo for recFSH
Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.

Active Comparator: Daily 300 IU recFSH
Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
Biological: RecFSH / follitropin beta
RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
Other Name: Follistim® AQ Cartridge

Drug: Placebo for SCH 900962

Supplied as a pre-filled syringe containing an identical solution when

compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall.

Primary Outcome Measures :
  1. Percentage of Participants With a Vital Pregnancy [ Time Frame: Vital pregnancy will be assessed by ultrasound at least 35 days after embryo transfer (with a timeframe of 35-42 days). Time from start of study treatment to embryo transfer is maximally 24 days. ]
    Vital pregnancy was defined as the presence of at least 1 fetus with heart activity at least 35 days (≥5 weeks) after embryo transfer in the controlled ovarian stimulation (COS) treatment cycle

Secondary Outcome Measures :
  1. Number of Oocytes Retrieved Per Attempt [ Time Frame: Maximally 21 days after the start of study treatment. ]
    The number of cumulus oocyte-complexes retrieved was summarized per treatment group and per attempt (= per started COS cycle).

  2. Live Birth Rate [ Time Frame: Approximately nine months after embryo transfer ]
    The live-birth rate is the percentage of participants with at least 1 live born infant after an ongoing pregnancy in the controlled ovarian stimulation (COS)treatment cycle relative to the number of participants treated.

  3. Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS) [ Time Frame: Up to approximately 1 month after oocyte pick-up ]

    Grade II (moderate OHSS) is characterized by distinct ovarian cysts (ovary size 8-10 cm), accompanied by abdominal pain and tension, nausea, vomiting, diarrhea.

    Grade III (severe OHSS) is characterized by enlarged cystic ovaries (ovary size >10 cm), accompanied by ascites and occasionally hydrothorax. Abdominal tension and pain may be severe. Pronounced hydrothorax together with an abdominal cavity filled with cysts and fluid elevating the diaphragm, may cause severe breathing difficulties. Large quantities of fluid inside the cysts and in the peritoneal and pleural cavities cause hemoconcentration and increased blood viscosity. In rare cases, the syndrome may further be complicated by the occurrence of thromboembolic phenomena.

  4. Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event [ Time Frame: Up to time of embryo transfer (maximum of 24 days after start of study drug) ]
    The number of participants who started stimulation but did not undergo embryo transfer due to (S)AEs will be compared between the treatment groups.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to provide written informed consent for trial P06029 as well as for the Frozen-Thawed Embryo Transfer (FTET) follow-up trial P06031, and for the pharmacogenetic analysis (if applicable).
  • Female and >=35 to <=42 years of age with indication for COS and IVF/ICSI.
  • Body weight ≥50.0 kg, body mass index (BMI) >=18.0 to <=32.0 kg/m2.
  • Regular spontaneous menstrual cycle with variation not outside the 24-35 days.
  • Ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed).
  • Results of clinical laboratory tests, cervical smear, physical examination within normal limits or clinically acceptable to the investigator.
  • Adhere to trial schedule.

Exclusion Criteria:

  • A recent history of/or any current endocrine abnormality.
  • A history of ovarian hyper-response or ovarian hyperstimulation syndrome (OHSS).
  • A history of/or current polycystic ovary syndrome.
  • More than 20 basal antral follicles <11 mm (both ovaries combined) in the early follicular phase.
  • Less than 2 ovaries or any other ovarian abnormality.
  • Unilateral or bilateral hydrosalpinx.
  • Intrauterine fibroids ≥5 cm or any clinically relevant pathology, which could impair embryo implantation or pregnancy continuation.
  • More than three unsuccessful COS cycles for IVF/ICSI since the last established ongoing pregnancy (if applicable).
  • A history of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment.
  • A history of recurrent miscarriage.
  • FSH >15.0 IU/L or luteinizing hormone (LH) >12.0 IU/L during the early follicular phase.
  • Positive for human immunodeficiency virus (HIV) or Hepatitis B.
  • Contraindications for the use of gonadotropins or gonadotropin releasing hormone (GnRH) antagonists.
  • A recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring regular treatment.
  • Smoking or recently stopped smoking (ie, within the last 3 months prior to signing informed consent).
  • A recent history or presence of alcohol or drug abuse.
  • The participant or the sperm donor has known gene defects, genetic abnormalities, or abnormal karyotyping, relevant for the current indication or for the health of the offspring.
  • Prior or concomitant medications disallowed by protocol.

Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01144416     History of Changes
Other Study ID Numbers: P06029
First Posted: June 15, 2010    Key Record Dates
Results First Posted: December 27, 2012
Last Update Posted: June 30, 2015
Last Verified: June 2015
Keywords provided by Merck Sharp & Dohme Corp.:
Reproductive Techniques, Assisted
Follicle Stimulating Hormone, Human
Fertilization In Vitro
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female
Follicle Stimulating Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs